Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. - Wikidata - awgldk - TriplyDB

Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas.

Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas.

http://www.wikidata.org/entity/Q33399473

about

Osteosarcoma in Korean children and adolescents TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI Management of pediatric head and neck rhabdomyosarcoma: A case-series of 36 patients Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.Treatment pathway of bone sarcoma in children, adolescents, and young adults Pediatric primary splenic angiosarcoma: an aggressive multidisciplinary approach to the oncologic management of a rare malignancy.Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.Metastatic extraskeletal Ewing's sarcoma treated with trabectedin: A case report.Targeted therapy for soft tissue sarcomas in adolescents and young adults.The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).Advances in emerging drugs for osteosarcoma.An update on chemotherapy for osteosarcoma.Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study.Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy.Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience.Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.Consensus and controversies regarding the treatment of rhabdomyosarcoma.Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: A large retrospective study Progress in the chemotherapeutic treatment of osteosarcoma

P2860

Q28083794-323CAB78-56CC-4A1D-B92A-B9A2129E2160 Q28540575-FEB889F3-6726-4EDE-935F-F63FCA7D4B5F Q30369053-0EA09FA1-12C8-47F7-97DA-58D74EFD339D Q33439510-9A8EC0DF-A487-4591-BF18-F9151464C270 Q33835657-EC80E28B-60DE-47CF-8827-A6F97633DE07 Q34969375-6AD3470B-B08C-41FD-A865-2CB44CFFB935 Q35758538-8A157AC1-3172-4A31-84B7-CF3F57E0719E Q36592309-CADA9767-FF13-4DA8-923C-598152447519 Q37256170-53DFC940-CA25-4A32-92AC-84604490325C Q37288603-72DFDA22-89D5-4F84-8F65-4077A97D6EDE Q37742014-0B0E12EC-67C0-47EF-A165-66D168771D69 Q38267782-9E161A9C-8A0C-43B0-A165-7D1240CC6ADC Q38372566-DDB64127-F150-41D5-A6D8-9446EDB2CC22 Q38506118-2C964CCD-F6F1-4EF5-8986-72B981CFE0C2 Q38619114-48E4B509-C151-45D1-A4B2-4991C2B1C1C0 Q38791215-7F863291-4CCB-4295-ACCB-341764DBD0D3 Q38865404-DAD615E1-DC97-49B1-8A40-C0B76C20687F Q39752805-8683C4D9-3934-4C27-837B-999B4CDAFF63 Q41093026-5CEF13E9-7BD8-4CAF-9580-9F4905320436 Q44252612-3688B3DD-5307-46A0-8602-F376E20C6ECF Q44611540-44293300-1805-487F-A0B2-7E57C4715666 Q47687872-90E17BAC-3EC4-4625-B52B-348666FDB296 Q57570538-517C0E74-769F-46E5-878E-0BFF0D57312C Q58572917-8850AD96-A019-4B9E-BC74-26287B39DAA9

P2860

Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas.

http://www.wikidata.org/entity/Q33399473

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Gemcitabine and docetaxel (GEM ...... refractory pediatric sarcomas.

@ast

Gemcitabine and docetaxel (GEM ...... refractory pediatric sarcomas.

@en

type

label

Gemcitabine and docetaxel (GEM ...... refractory pediatric sarcomas.

@ast

Gemcitabine and docetaxel (GEM ...... refractory pediatric sarcomas.

@en

prefLabel

Gemcitabine and docetaxel (GEM ...... refractory pediatric sarcomas.

@ast

Gemcitabine and docetaxel (GEM ...... refractory pediatric sarcomas.

@en

P1433

Q33399473-8054D380-C9A8-43D9-8664-1CCBA6C5C1FD

P1476

Q33399473-D68A44EB-7EBD-424E-A921-864DE1381AD4

P2093

Q33399473-1AB533D6-8534-4485-A332-BB789191A8E2

Q33399473-2CACCBA2-A4E9-4384-AB6E-C76CFF439D7C

Q33399473-51C5E615-B2A0-4111-ADD6-F8FB136E3453

Q33399473-63C2607B-DF98-461F-AF3E-CE4CE60C40F7

Q33399473-9AF87CE9-8B37-4CE9-9BC9-61363298293C

Q33399473-B004B43B-181E-406D-84EC-8C04D1F0A646

Q33399473-B958F2D3-EAAB-4F10-B180-6EED4694161E

Q33399473-C8A8DB70-78CB-41AC-B071-F480944071A9

Q33399473-DDA0B1D7-E9FD-4BDE-9D1D-4815EDA9E5F0

Q33399473-EEDF53C6-08AC-4DAA-88C7-001D3F973C04

P2860

Q33399473-1607E4A9-8F0A-43B3-93AE-2072C404B9ED

Q33399473-1E52D3E0-5BBB-4FF2-9206-5955D662F020

Q33399473-71A4DB6C-B107-4CDE-8F40-6A8409A96904

Q33399473-797D3504-3A27-466C-B165-DA69A320B5FE

Q33399473-C0DDB658-0AAD-455E-8A36-4F4B3238012B

Q33399473-C37DF2EC-B047-4B97-B9CC-D8908A97AF91

Q33399473-C4484D2B-AD78-4DCA-9AD8-F0EC9A251CFB

P304

Q33399473-1C0AE6F1-C852-43D0-99EB-3C47891065A3

P31

Q33399473-C45D4322-4262-4E28-B0D7-9CB556FA3383

P356

Q33399473-920F53BC-97AD-4635-BE62-F09B1EEF2B71

P433

Q33399473-388F7475-81B1-49F0-8369-B662628F612E

P478

Q33399473-C29D26F7-694D-4F93-B9AF-73F40B97E267

P577

Q33399473-431C7B15-6277-4DE8-8121-EBBCDC537C90

P698

Q33399473-1F53F002-0AF2-4E55-B0BE-6CFD63FFACB6

P356

P1433

Pediatric Blood & Cancer

P1476

Gemcitabine and docetaxel (GEM ...... refractory pediatric sarcomas.

@en

P2093

Adina Alazraki

http://www.w3.org/2001/XMLSchema#string

Bradley A George

http://www.w3.org/2001/XMLSchema#string

Dana Clark

http://www.w3.org/2001/XMLSchema#string

Howard M Katzenstein

http://www.w3.org/2001/XMLSchema#string

Karen Wasilewski-Masker

http://www.w3.org/2001/XMLSchema#string

Louis Rapkin

http://www.w3.org/2001/XMLSchema#string

Melissa Martin

http://www.w3.org/2001/XMLSchema#string

Muna Qayed

http://www.w3.org/2001/XMLSchema#string

Pam Brill

http://www.w3.org/2001/XMLSchema#string

Thomas A Olson

http://www.w3.org/2001/XMLSchema#string

P2860

Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data.

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.

Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.

Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.

Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group.

Prognostic factors and outcomes for osteosarcoma: An international collaboration

P304

854-858

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.24101

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22302783

http://www.w3.org/2001/XMLSchema#string